| Seekyo–Andrew Lloyd Associates: public relations, 202001 service existent by ALA |
2020-01-20 |
| Seekyo–EU (govt): credit, 202001 EIF Investment Initiation Loan €150k |
2020-01-20 |
| Seekyo–France (govt): credit, 202001 convertible bond €250k financing from French Tech Seed Fund managed by Bpifrance |
2020-01-20 |
| Seekyo–SEVERAL: investment, 202001 seed financing round €400k from investors from three business angel networks |
2020-01-20 |
| Piramal–Onex Corp: investment, 201901– acquisition Decision Resources by Clarivate Analytics from Piral Enterprises Ltd for $900m cash + $50m shares |
2020-01-17 |
| BioNTech–Covington & Burling: legal services, 202001 supply service legal counsel with regard to merger acquisition of Neon Therapeutics |
2020-01-16 |
| Neon Therapeutics–BioNTech: investment, 202001–acquisition merger $67m by BioNTech in all-stock transaction with 0.063 ADSs/share = $2.18/share |
2020-01-16 |
| Neon Therapeutics–Goodwin Procter: legal services, 202001 supply service legal counsel with regard to merger acquisition by BioNTech |
2020-01-16 |
| Neon Therapeutics–Ondra Partners: financial services, 202001 supply service excl financial advisor with regard to merger acquisition by BioNTech |
2020-01-16 |
| Scope Fluidics–Mindset Communication Support: public relations, 202001 service existent by Mindset CS |
2020-01-16 |
| Danaher–Sophia Genetics: genomic technologies, 202001– collab ww expansion IDT NGS enrichment products with Sophia Genetics DDM for clinical research |
2020-01-15 |
| Fibrocor Therapeutics–Galapagos: investment, 202001 equity investment by Galapagos as part of expanded collaboration |
2020-01-15 |
| Galapagos–Fibrocor Therapeutics: fibrosis drug, 202001– collab developm expansion excl license option for 4 addit small molecule inhibitor programmes |
2020-01-15 |
| Astellas–Adaptimmune: allogenic T-cell therapies, 202001– collab r+d CAR-T + TCR therapies with up to $897.5m for ADAP + up to $552.5m for Astellas |
2020-01-14 |
| Urania Therapeutics–France (govt): credit, 202001 repayable advances €850k from Bpifrance |
2020-01-14 |
| Urania Therapeutics–France (govt): grant, 202001 subsidies €850k from Bpifrance |
2020-01-14 |
| Andrew Alliance–Waters: investment, 202001 acquisition by existent investor Waters |
2020-01-13 |
| Daiichi Sankyo–ERS Genomics: CRISPR technology, 202001– license ww excl €na for internal r+d |
2020-01-13 |
| Domain Therapeutics–SEVERAL: credit, 202001 debt financing €6m fomr Bpifrance + BPALC + CIC + CEGEE |
2020-01-13 |
| Illumina–Roche: genomic cancer testing, 202001–201412 collab €na strategic alliance non-excl for NGS-based cancer testing for IVD + CDx |
2020-01-13 |
| Incyte–MorphoSys: tafasitamab, 202001– collab + ww excl license incl US co-commercialisation $750m upfront + $1.1b milestones |
2020-01-13 |
| MorphoSys–Incyte: investment, 202001 equity investment $150m in new ADSs at premium to share price as part of tafasitamab collab/license agreement |
2020-01-13 |
| Iovance–Cellectis: gene editing technology, 202001– collab + license ww excl for TILs in several cancer indications |
2020-01-12 |
| NBE Therapeutics–Boehringer: investment, 202001 financing round Series C totalling $22m incl existing + co-lead investor BIVF |
2020-01-10 |
| NBE Therapeutics–OTHER: investment, 202001 financing round Series C USD22m incl all existing private shareholders |
2020-01-10 |
| NBE Therapeutics–PPF Group: investment, 202001 financing round Series C totalling $22m incl existing + co-lead investor PPF Group |
2020-01-10 |
| NBE Therapeutics–SEVERAL: investment, 202001 financing round Series C USD22m led by existing investors BIVF + PPF Group wih all private investors |
2020-01-10 |
| Alderaan Biotechnology–Advent France Biotechnology: investment, 202001 financing round Series A totalling €18.5m incl existing investor AFB |
2020-01-09 |
| Alderaan Biotechnology–Medicxi: investment, 202001 financing round Series A totalling €18.5m incl new investor Medicxi |
2020-01-09 |
| Alderaan Biotechnology–SEVERAL: investment, 202001 financing round Series A €18.5m with Advent France Biotechnology + Medicxi |
2020-01-09 |
| Almirall–23andMe: therapeutic antibodies, 202001– license ww to bispecific MAb blocking all 3 isoforms of IL-36 |
2020-01-09 |
| Almirall–WuXi PharmaTech: therapeutic antibodies, 202001– collab strategic r+d bispecific Abs for dermatology using WuXiBody antibody technology |
2020-01-09 |
| Sanofi–Nurix Therapeutics: protein degradation drugs, 202001– collab strategic ww $55m upfront + $2.5m milestones using DELigase platform |
2020-01-09 |
| Eyevensys–Bellevue: investment, 202001 financing round Series B totalling $30m incl new + co-investor Pureos Bioventures |
2020-01-08 |
| Eyevensys–Boehringer: investment, 202001 financing round Series B totalling $30m incl existing + lead investor Boehringer Ingelheim Venture Fund |
2020-01-08 |
| Eyevensys–CapDecisif: investment, 202001 financing round Series B totalling $30m incl existing + co-investor CapDecisif |
2020-01-08 |
| Eyevensys–France (govt): investment, 202001 financing round Series B totalling $30m incl existing + co-investors Bpifrance + Inserm Transfert |
2020-01-08 |
| Eyevensys–Pontifax: investment, 202001 financing round Series B totalling $30m incl existing + co-investor Pontifax |
2020-01-08 |
| Eyevensys–Quark Venture: investment, 202001 financing round Series B totalling $30m incl new + co-investor GHS Fund (Quark Venture + GF Securities) |
2020-01-08 |
| Eyevensys–RooneyPartners: public relations, 202001 service existent by RooneyPartners |
2020-01-08 |
| Eyevensys–SEVERAL: investment, 202001 financing round Series B $30m led by Boehringer Ingelheim Venture Fund |
2020-01-08 |
| NorthSea Therapeutics–BioGeneration Ventures: investment, 202001 financing round Series B totalling €36m incl existing + co-investor BGV |
2020-01-08 |
| NorthSea Therapeutics–Forbion: investment, 202001 financing round Series B totalling €36m incl existing + co-investor Forbion |
2020-01-08 |
| NorthSea Therapeutics–New Science Ventures: investment, 202001 financing round Series B totalling €36m incl existing + co-investor NSV |
2020-01-08 |
| NorthSea Therapeutics–Novo Group: investment, 202001 financing round Series B totalling €36m incl existing + co-investor Novo Seeds |
2020-01-08 |
| NorthSea Therapeutics–SEVERAL: investment, 202001 financing round Series B €36m led by new investor VenBio |
2020-01-08 |
| NorthSea Therapeutics–Sofinnova: investment, 202001 financing round Series B totalling €36m incl new + co-investor Sofinnova Investments |
2020-01-08 |
| NorthSea Therapeutics–VenBio: investment, 202001 financing round Series B totalling €36m incl new + lead investor VenBio Partners |
2020-01-08 |
| Riemser–Esteve: investment, 202001– acquisition €na of Riemser from Ardian by Esteve |
2020-01-08 |
| Wellington Partners–MC Services: public relations, 202001 service existent by MC Services |
2020-01-08 |
| AstraZeneca–MiNA Therapeutics: saRNA therapeutics, 202001– collab €na research + license option for saRNA therapeutics for metabolic diaseses |
2020-01-07 |
| Boehringer–PhoreMost: drug discovery services, 202001– collab €na multi-project target discovery using Siteseeker platform |
2020-01-07 |
| MiNA Therapeutics–Trophic Communications: public relations, 202001 service existent by Trophic Communications |
2020-01-07 |
| PharmAkea–Galecto Biotech: investment, 202001– merger €na with new Galecto Inc in US with operational HQ in Copenhagen ANNOUNCED |
2020-01-07 |
| VectivBio–Cowen: investment, 202001 1st financing round totalling $35m incl Cowen Healthcare Investors |
2020-01-07 |
| VectivBio–France (govt): investment, 202001 1st financing round totalling $35m incl Bpifrance + Inserm Transfer Initiative |
2020-01-07 |
| VectivBio–Novo Group: investment, 202001 1st financing round totalling $35m incl Novo Holdings |
2020-01-07 |
| VectivBio–OrbiMed: investment, 202001 1st financing round totalling $35m incl OrbiMed |
2020-01-07 |
| VectivBio–SEVERAL: investment, 202001 1st financing round $35m with Versant Ventures + Orbimed + Novo Holdings + Bpifrance et al. |
2020-01-07 |
| VectivBio–Tekla Capital: investment, 202001 1st financing round totalling $35m incl Tekla Healthcare Investors |
2020-01-07 |
| VectivBio–Versant Ventures: investment, 202001 1st financing round totalling $35m incl Versant Ventures |
2020-01-07 |
| VectivBio–WPP: public relations, 202001 service existent by Glover Park Group |
2020-01-07 |
| Velabs Therapeutics–Alytas Therapeutics: therapeutic antibodies, 202001– license excl for developm + commercialisation of Abs in field of senescence |
2020-01-07 |
| Integrated Biotherapeutics–Novo Group: investment, 202001 investment $3.9m in IBT Vaccines by Novo REPAIR Impact Fund |
2020-01-06 |
| Pharma Omnium–Novo Group: investment, 202001 investment €7m by Novo REPAIR Impact fund into Mutabilis |
2020-01-06 |
| Nabriva–Sam Brown: public relations, 201912 service existent by Sam Brown Inc |
2019-12-20 |
| Nabriva–SEVERAL: investment, 201912 registered direct offering $20m with 13.8m pairs ordinary share + warrant at $1.45/pair to institutional investors |
2019-12-20 |
| Savara–SEVERAL: investment, 201912– private placement $26.8m (with potential total proceeds of $75m) to institutional investors leb by Bain Capital LS |
2019-12-20 |
| CureVac–Genmab: investment, 201912 equity investment €20m by Genmab as part of strategic alliance |
2019-12-19 |
| Genmab–CureVac: mRNA-based antibody therapeutics, 201912– collab research + license agreem 5y $10m upfront using CureVac mRNA + Genmab Ab technologies |
2019-12-19 |
| Kinnate Biopharma–Nextech Invest: investment, 201912 financing round Series B totalling $74.5m incl new investor Nextech Invest Ltd |
2019-12-19 |
| Kinnate Biopharma–OrbiMed: investment, 201912 financing round Series B totalling $74.5m incl new investor OrbiMed |
2019-12-19 |
| Kinnate Biopharma–SEVERAL: investment, 201912 financing round Series B $74.5m from OrbiMed + Nextech Invest + Vida Ventures + Foresite + Eshelman |
2019-12-19 |
| Promega–Merck (DE): CRISPR technology, 201912– license to CRISPR IP io from Merck to Promega to develop CRISPR-edited cell lines |
2019-12-19 |
| BC Platforms–SEVERAL: investment, 201912 financing round Series C $15m led by Iqvia + incl Debiopharm Innovation Fund + Tesi |
2019-12-18 |
| Genomill Health–Avohoidon Tutkimussäätiö: investment, 201912 financing round incl co-investor Avohoidon Tutkimussäätiö |
2019-12-18 |
| Genomill Health–SEVERAL: investment, 201912 financing round led by Voima Ventures with Avohoidon Tutkimussäätiö |
2019-12-18 |
| Genomill Health–Voima Ventures: investment, 201912 financing round incl lead investor Voima Ventures |
2019-12-18 |
| KCR CRO–Veeva Systems: clinical research software, 201912– supply adoption of Veeva Vault CTMS by KCR |
2019-12-18 |
| Pathios Therapeutics–SEVERAL: investment, 201912 financing round Series A $8.8m with Canaan + MRCF managed by Brandon Capital |
2019-12-18 |
| Cellestia Biotech–SEVERAL: investment, 201912 financing round Series B CHF20m from FC Capital + PPF Group + Partners Investment + private investors |
2019-12-17 |
| Edinburgh Molecular Imaging–SEVERAL: investment, 201912 financing round £3.1m from new investor Caribou Property + existing investors |
2019-12-17 |
| Resistell–SEVERAL: investment, 201912 financing round Series A CHF3.5m |
2019-12-17 |
| Seer–aMoon: investment, 201912 financing round Series D totalling $55m incl lead investor aMoon Fund |
2019-12-17 |
| Seer–SEVERAL: investment, 201912 financing round Series D $55m led by aMoon + incl T Rowe Price + all existing plus other new investors |
2019-12-17 |
| Augustine Therapeutics–SEVERAL: investment, 201912 seed financing round €4.2m from V-Bio Ventures + PMV + Advent France + Gemma Vrisius + VIB |
2019-12-16 |
| Flagship Pioneering–WPP: public relations, 201912 service existent by Ogilvy |
2019-12-16 |
| Promethera–SEVERAL: investment, 201912 financing round Series D extension €7.5m bringing total round to €47.2m |
2019-12-16 |
| Aelis Farma–NewCap: public relations, 201912 service existent by NewCap |
2019-12-13 |
| Aelis Farma–SEVERAL: grant, 201912c research grants totalling €9m from various organisations incl US NIDA |
2019-12-13 |
| Aelis Farma–SEVERAL: investment, 201912 financing round €11m incl Region Nouvelle Aquitaine + Inserm Transfert Initiative + Bpifrance |
2019-12-13 |
| Start Codon–One Nucleus: business services, 201912– service support of start-ups participating in Start Codon accelerator programme by One Nucleus |
2019-12-11 |
| Abcalis–Germany (govt): grant, 201912 EXIST research transfer grant for founding from BMWi (plus ESF grant) |
2019-12-10 |
| Charles River–Bit Bio: drug discovery technology, 201912– collab strategic excl discovery + safety services partnership reprograming of human cells |
2019-12-10 |
| ImmunOs Therapeutics–SEVERAL: investment, 201912 financing round Series CHF15m co-led by Pfizer Ventures + BioMedPartners |
2019-12-10 |
| Inscripta–SEVERAL: investment, 201912 financing round Series D $125m led by Paladin Capital Group |
2019-12-10 |
| Schauenburg–JP Scientific: SPE technology, 201912– ww commercial license + supply to Markes from JP Scientific Ltd |
2019-12-10 |
| Algiax Pharmaceuticals–SEVERAL: investment, 201912 financing round €5.5m incl new investor Occident |
2019-12-09 |
| EMBL–Bruker: microscope, 201912 supply existent early customer EMBL for new Luxendo TruLive3D Imager |
2019-12-09 |
| Epidarex Capital–Zyme Communications: public relations, 201912 service existent by Zyme |
2019-12-09 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo-2019.png){kind=logo}
Date![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px](/banner/iito-20181119-650-065-lsus-life-sciences-usa-com.jpg)
![Picture [iito] LSUS iitoLifeScience Transatlantic Life Sciences 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
